Hikma shares drop 7% on weaker margins despite solid revenue, maintained outlook

Hikma Pharmaceuticals shares fell over 7% after its first-half 2025 results revealed a 5.7% rise in group revenue to $1.66 billion but a 7.2% decline in core operating profit and a narrowed group margin to 22.5%. The market reaction was driven by significant margin compression in its injectables and U.S. generics segments, with injectables' margin falling to 30% from 36.3% due to increased U.S. competition and acquisition dilution, leading to a reduced full-year margin forecast for that key segment despite reaffirmed overall company guidance.

Analysis

Hikma Pharmaceuticals experienced a significant share price decline of over 7% despite reporting a 5.7% increase in first-half group revenue to $1.66 billion. The negative market reaction was driven by a pronounced contraction in profitability, with core operating profit falling 7.2% to $373 million and the group margin narrowing to 22.5% from 25.6% a year earlier. The primary concern stems from the Injectables division, the company's largest segment, where strong revenue growth of 12.2% was overshadowed by an 8% drop in core EBIT and a margin collapse to 30% from 36.3%, attributed to U.S. competition and the dilutive effect of the Xellia acquisition. This pressure is expected to persist, as the company lowered its full-year margin guidance for this key segment to 32%–33% from the “mid-30s,” even while reaffirming overall group guidance. The U.S. Generics business also faced headwinds, with revenue slipping 0.9% and its margin declining to 17.6% from 19.7% due to higher R&D investment. While the Branded segment remained relatively stable and the company noted a potential future catalyst from a new contract manufacturing agreement, the market is evidently focused on the material and ongoing margin erosion in its core businesses.

Key Decisions for Investors

• Investors should scrutinize future earnings for signs of margin stabilization in the Injectables segment, as the revised full-year guidance suggests the current competitive and integration pressures are not transient.
• Consider whether the 7% share price drop adequately prices in the sustained margin pressure, or if it presents an opportunity given that the company reaffirmed its full-year group revenue and EBIT guidance.
• Monitor progress on the new contract manufacturing agreement for the Columbus facility, as this represents a potential positive catalyst that could help offset weakness in the U.S. Generics segment.
• Weigh the near-term profitability challenges against the continued top-line growth in the Injectables segment and the relative stability of the Branded business, which is expected to see a foreign exchange tailwind in the second half.